OUTLOOK THERAPEUTICS INC (OTLK) Fundamental Analysis & Valuation

NASDAQ:OTLKUS69012T3059

Current stock price

0.219 USD
+0.01 (+4.29%)
At close:
0.2189 USD
0 (-0.05%)
After Hours:

This OTLK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OTLK Profitability Analysis

1.1 Basic Checks

  • OTLK had negative earnings in the past year.
  • OTLK had a negative operating cash flow in the past year.
  • In the past 5 years OTLK always reported negative net income.
  • OTLK had a negative operating cash flow in each of the past 5 years.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -563.97%, OTLK is not doing good in the industry: 94.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -563.97%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K -1.5K

1.3 Margins

  • Looking at the Gross Margin, with a value of 19.23%, OTLK is in the better half of the industry, outperforming 71.37% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for OTLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

0

2. OTLK Health Analysis

2.1 Basic Checks

  • OTLK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OTLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -60.82, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
  • OTLK has a Altman-Z score of -60.82. This is amonst the worse of the industry: OTLK underperforms 91.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.82
ROIC/WACCN/A
WACC8.59%
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

2.3 Liquidity

  • A Current Ratio of 0.35 indicates that OTLK may have some problems paying its short term obligations.
  • OTLK has a worse Current ratio (0.35) than 91.88% of its industry peers.
  • A Quick Ratio of 0.28 indicates that OTLK may have some problems paying its short term obligations.
  • OTLK's Quick ratio of 0.28 is on the low side compared to the rest of the industry. OTLK is outperformed by 92.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.28
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

3

3. OTLK Growth Analysis

3.1 Past

  • OTLK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.11%.
EPS 1Y (TTM)-51.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, OTLK will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.99% on average per year.
  • OTLK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.18% yearly.
EPS Next Y-49.76%
EPS Next 2Y-4.93%
EPS Next 3Y17.82%
EPS Next 5Y10.99%
Revenue Next Year251.93%
Revenue Next 2Y160.65%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%

3.3 Evolution

OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 2033 10M 20M 30M 40M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -100 -200 -300

0

4. OTLK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OTLK. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OTLK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • OTLK's earnings are expected to grow with 17.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.93%
EPS Next 3Y17.82%

0

5. OTLK Dividend Analysis

5.1 Amount

  • OTLK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OTLK Fundamentals: All Metrics, Ratios and Statistics

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (4/2/2026, 8:00:02 PM)

After market: 0.2189 0 (-0.05%)

0.219

+0.01 (+4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-13
Inst Owners8.23%
Inst Owner Change64.57%
Ins Owners0.04%
Ins Owner Change0%
Market Cap18.19M
Revenue(TTM)297.50K
Net Income(TTM)-102.86M
Analysts78
Price Target3.95 (1703.65%)
Short Float %4.58%
Short Ratio1.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.32%
Min EPS beat(2)-19.83%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)0.99%
Min EPS beat(4)-37.09%
Max EPS beat(4)34.42%
EPS beat(8)5
Avg EPS beat(8)40.51%
EPS beat(12)8
Avg EPS beat(12)30.37%
EPS beat(16)9
Avg EPS beat(16)17.3%
Revenue beat(2)0
Avg Revenue beat(2)-112.55%
Min Revenue beat(2)-123.57%
Max Revenue beat(2)-101.54%
Revenue beat(4)0
Avg Revenue beat(4)-84.09%
Min Revenue beat(4)-123.57%
Max Revenue beat(4)-11.26%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.91%
PT rev (3m)-59.21%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)36.43%
Revenue NQ rev (1m)-11.41%
Revenue NQ rev (3m)49.15%
Revenue NY rev (1m)11.89%
Revenue NY rev (3m)-20.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -563.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.23%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.28
Altman-Z -60.82
F-Score5
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.56%
EPS Next Y-49.76%
EPS Next 2Y-4.93%
EPS Next 3Y17.82%
EPS Next 5Y10.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year251.93%
Revenue Next 2Y160.65%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%
EBIT growth 1Y29.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.46%
OCF growth 3YN/A
OCF growth 5YN/A

OUTLOOK THERAPEUTICS INC / OTLK Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OUTLOOK THERAPEUTICS INC (OTLK) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OTLK.


Can you provide the valuation status for OUTLOOK THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OUTLOOK THERAPEUTICS INC (OTLK). This can be considered as Overvalued.


Can you provide the profitability details for OUTLOOK THERAPEUTICS INC?

OUTLOOK THERAPEUTICS INC (OTLK) has a profitability rating of 1 / 10.


How financially healthy is OUTLOOK THERAPEUTICS INC?

The financial health rating of OUTLOOK THERAPEUTICS INC (OTLK) is 0 / 10.


Can you provide the expected EPS growth for OTLK stock?

The Earnings per Share (EPS) of OUTLOOK THERAPEUTICS INC (OTLK) is expected to decline by -49.76% in the next year.